Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by Teamwork Financial Advisors LLC

Teamwork Financial Advisors LLC grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 34,828 shares of the medical equipment provider’s stock after acquiring an additional 195 shares during the period. Intuitive Surgical comprises about 2.4% of Teamwork Financial Advisors LLC’s investment portfolio, making the stock its 14th biggest holding. Teamwork Financial Advisors LLC’s holdings in Intuitive Surgical were worth $17,110,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of ISRG. Capital Research Global Investors acquired a new position in Intuitive Surgical in the first quarter worth about $374,390,000. Vanguard Group Inc. grew its stake in Intuitive Surgical by 1.6% in the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after purchasing an additional 493,126 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Intuitive Surgical by 51.2% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock worth $356,524,000 after purchasing an additional 302,382 shares in the last quarter. Strategic Financial Concepts LLC grew its stake in Intuitive Surgical by 40,221.4% in the second quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider’s stock worth $1,184,000 after purchasing an additional 265,461 shares in the last quarter. Finally, GQG Partners LLC bought a new position in Intuitive Surgical in the first quarter worth about $99,523,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. BTIG Research raised their target price on shares of Intuitive Surgical from $494.00 to $518.00 and gave the stock a “buy” rating in a report on Monday. Truist Financial raised their target price on shares of Intuitive Surgical from $520.00 to $570.00 and gave the stock a “buy” rating in a report on Monday. Barclays raised their target price on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. Citigroup raised their target price on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Finally, Royal Bank of Canada lifted their price target on Intuitive Surgical from $515.00 to $525.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Six equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average price target of $484.15.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Amy L. Ladd sold 450 shares of Intuitive Surgical stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the transaction, the director now directly owns 821 shares in the company, valued at approximately $402,519.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, EVP Myriam Curet sold 2,818 shares of Intuitive Surgical stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $1,291,010.34. Following the completion of the sale, the executive vice president now owns 298 shares of the company’s stock, valued at approximately $136,522.74. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Amy L. Ladd sold 450 shares of Intuitive Surgical stock in a transaction on Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the sale, the director now directly owns 821 shares of the company’s stock, valued at approximately $402,519.88. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 53,120 shares of company stock worth $25,528,753. 0.90% of the stock is owned by insiders.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $473.73 on Friday. The firm has a market cap of $168.03 billion, a price-to-earnings ratio of 85.51, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $496.48. The firm’s 50 day moving average price is $482.69 and its two-hundred day moving average price is $436.91.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.24. The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.18 earnings per share. As a group, equities analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.